Systemic Lipoplatin infusion results in preferential tumor uptake in human studies - PubMed

Affiliations

• PMID: 16080562

Free article

Clinical Trial

Systemic Lipoplatin infusion results in preferential tumor uptake in human studies

Teni Boulikas et al. Anticancer Res. 2005 Jul-Aug.

Free article

Abstract

Lipoplatin, a liposomal formulation of cisplatin, was developed with almost negligible nephrotoxicity, ototoxicity and neurotoxicity, as demonstrated in preclinical and Phase I human studies. A polyethylene-glycol coating of the liposome nanoparticles is supposed to result in tumor accumulation of the drug by extravasation through the altered tumor vasculature. We explored the hypothesis that intravenous infusion of Lipoplatin results in tumor targeting in four independent patient cases (one with hepatocellular adenocarcinoma, two with gastric cancer and one with colon cancer) who underwent Lipoplatin infusion followed by a prescheduled surgery approximately 20 h later. Direct measurement of the platinum levels in specimens from the excised tumors and normal tissues showed that the total platinum levels were on average 10-50 times higher in malignant tissue compared to the adjacent normal tissue specimens; most effective targeting was observed in colon cancer, with an accumulation up to 200-fold higher in colon tumors compared to normal colon tissue. Of the several surgical specimens, gastric tumors displayed the highest levels of total platinum suggesting Lipoplatin as a candidate anticancer agent for gastric tumors; gastric tumor specimens had up to 260 micrograms platinum /g tissue, that was higher than any tissue level in animals treated at much higher doses. Fat tissue displayed a high accumulation of total platinum in surgical specimens in three different patients, correlating to the lipid capsule of cisplatin in its Lipoplatin formulation. It was also inferred that normal tissue had more platinum trapped in the tissue but not reacted with macromolecules, whereas tumor tissue displayed platinum that reacted with cellular macromolecules; the data were consistent with a model where Lipoplatin damages more tumor compared to normal cells. In conclusion, Lipoplatin has the ability to preferentially concentrate in malignant tissue both of primary and metastatic origin following intravenous infusion to patients. In this respect, Lipoplatin emerges as a very promising drug in the arsenal of chemotherapeutics.

Similar articles

• Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.

  Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V, Stathopoulos JG. Stathopoulos GP, et al. Oncol Rep. 2005 Apr;13(4):589-95. Oncol Rep. 2005. PMID: 15756428 Clinical Trial.

• Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

  Boulikas T. Boulikas T. Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218. doi: 10.1517/13543780903114168. Expert Opin Investig Drugs. 2009. PMID: 19604121 Review.

• Liposomal cisplatin: a new cisplatin formulation.

  Stathopoulos GP. Stathopoulos GP. Anticancer Drugs. 2010 Sep;21(8):732-6. doi: 10.1097/CAD.0b013e32833d9adf. Anticancer Drugs. 2010. PMID: 20671511 Review.

• Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.

  Jehn CF, Boulikas T, Kourvetaris A, Possinger K, Lüftner D. Jehn CF, et al. Anticancer Res. 2007 Jan-Feb;27(1A):471-5. Anticancer Res. 2007. PMID: 17352269 Clinical Trial.

• Low renal toxicity of lipoplatin compared to cisplatin in animals.

  Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, Boulikas T. Devarajan P, et al. Anticancer Res. 2004 Jul-Aug;24(4):2193-200. Anticancer Res. 2004. PMID: 15330160

Cited by

• Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation.

  Charest G, Paquette B, Fortin D, Mathieu D, Sanche L. Charest G, et al. J Neurooncol. 2010 Apr;97(2):187-93. doi: 10.1007/s11060-009-0011-5. Epub 2009 Sep 17. J Neurooncol. 2010. PMID: 19760366 Free PMC article.

• Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.

  Tippayamontri T, Kotb R, Paquette B, Sanche L. Tippayamontri T, et al. Invest New Drugs. 2011 Dec;29(6):1321-7. doi: 10.1007/s10637-010-9494-3. Epub 2010 Jul 24. Invest New Drugs. 2011. PMID: 20658169

• Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations.

  Acland M, Lokman NA, Young C, Anderson D, Condina M, Desire C, Noye TM, Wang W, Ricciardelli C, Creek DJ, Oehler MK, Hoffmann P, Klingler-Hoffmann M. Acland M, et al. Cancers (Basel). 2022 Jun 2;14(11):2763. doi: 10.3390/cancers14112763. Cancers (Basel). 2022. PMID: 35681748 Free PMC article.

• Liposomal Formulations in Clinical Use: An Updated Review.

  Bulbake U, Doppalapudi S, Kommineni N, Khan W. Bulbake U, et al. Pharmaceutics. 2017 Mar 27;9(2):12. doi: 10.3390/pharmaceutics9020012. Pharmaceutics. 2017. PMID: 28346375 Free PMC article. Review.

• Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer.

  Stathopoulos GP, Stathopoulos J, Dimitroulis J. Stathopoulos GP, et al. Oncol Lett. 2012 Nov;4(5):1013-1016. doi: 10.3892/ol.2012.836. Epub 2012 Jul 30. Oncol Lett. 2012. PMID: 23162642 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • HighWire

• Other Literature Sources

  • The Lens - Patent Citations Database